Dopamine D2 receptor gene −141C Insertion/Deletion polymorphism in Turkish schizophrenic patients
- 193 Downloads
Schizophrenia is a chronic and neuropsychiatric disease that affects about 0.5–1% of the world’s population. An increase in dopamine and dopamine D2 receptor (DRD2) gene products has been well described in schizophrenic patients. Several groups have studied the relationship between dopaminergic hyperactivity and cellular communications have obtained discordant results. Studies searching for the relationship between the schizophrenia and DRD2 gene have gained more interest. Our objective was to determine the relationships among schizophrenic symptoms in schizophrenia subtypes and severity of symptoms in terms of DRD2 gene −141C Insertion/Deletion [Ins/Del; I/D] polymorphism by PCR-RFLP (polymerase chain reaction-restriction fragment length polymorphism) assay method. Genomic DNA was prepared from peripheral blood by using salt extraction method. After amplification of genomic DNA, PCR products were digested with BstNI restriction enzyme for the detection of DRD2 gene −141C Ins/Del polymorphism in 73 schizophrenic patients and 60 healthy control subjects. The allelic frequencies of the DRD2 gene −141C Ins/Del polymorphism in case and control groups were 79.5 and 77.5% for I allele; 20.5 and 22.5% for D allele respectively. There was no significant difference in frequencies of genotypes and alleles between the two groups. In schizophrenic and control subjects, there were no significant relationship in severity of the disease and schizophrenia types among the −141C Ins/Del genotypes and alleles.
KeywordsDRD2 gene Polymorphism Schizophrenia −141C Ins/Del
This study was supported by a grant of the Research Foundation of University of Eskisehir Osmangazi, Turkey (Grant No. 200011027).
- 7.Mihara K, Kondo T, Suzuki A, Yasui N, Ona S, Otani K et al (2001) No relationship between −141C Ins/Del polymorphsim in the promoter region of dopamine D2 receptor and extrapyramidal adverse effects of selective dopamine D2 antagonists in schizophrenic patients: a preliminary study. Psychiatry Res 101:33–38CrossRefPubMedGoogle Scholar
- 17.Stöber G, Jatzke S, Heils A, Jungkunz G, Knapp M, Mössner R et al (1998) Insertion/Deletion variant (−141 C Ins/Del) in the 5′ regulatory region of the dopamine D2 receptor gene: lack of association with schizophrenia and bipolar affective disorder. J Neural Transm 105:101–109CrossRefPubMedGoogle Scholar
- 18.Mihara K, Suzuki A, Kondo T, Nagashima U, Ona S, Otani K et al (2000) No relationship between Taq 1 a polymorphism of dopamine D2 receptor gene and extrapyramidal adverse effects of selective dopamine D2 antagonists, bromperidol and namonapride in schizophrenia: a preliminary study. Am J Med Genet 96:422–424CrossRefPubMedGoogle Scholar
- 21.American Psychiatry Association (APA) (1994) Diagnostic and statistical manual of mental disorders, 4th edn. DSM-IV, Washington DCGoogle Scholar